The Times Australia
Google AI
PR Newswire

.

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start

ZÜRICH, Nov. 9, 2020 /PRNewswire/ -- Concept Medical Inc.,[1] focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the SirPAD (Sirolimus in Peripheral Artery Disease) trial.

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start The study is initiated by Prof. Dr. med Nils Kucher (also the Principal Investigator) in charge of the Clinic of Angiology at the University Hospital Zurich, Switzerland.

SirPAD[2] is the first All-Comer randomized controlled clinical trial (RCT) investigating major adverse limb events in PAD patients with lesions below the inguinal ligament.

SirPAD[3] is investigator-initiated, single-center, randomized, non-inferiority, open-label clinical trial investigating whether the use of MagicTouch PTA[4] sirolimus-coated balloon catheters in patients with peripheral artery disease of the femoro-popliteal or below-the-knee segment is not inferior to that of uncoated balloon catheters for major clinical outcomes (unplanned major amputation, target limb re-vascularization). Total of 1200 patients are to be randomized 1:1 (600 patients per treatment group).

The primary objective is to evaluate whether the use of sirolimus-coated balloon catheters (MagicTouch PTA[5]) is non-inferior to uncoated balloon catheters in infra-inguinal angioplasty to prevent one-year major adverse limb events (MALE), including unplanned major amputation of the target limb and target lesion re-vascularization for critical limb ischemia, in a representative population of patients with PAD (`all-comers`). If the criterion for non-inferiority is confirmed, the study will test whether sirolimus-coated catheters (MagicTouch PTA[6]) are superior to uncoated catheters for important secondary outcomes and for the primary outcome itself according to pre-specified criteria for hierarchical analysis.

The index patient was successfully enrolled on 3rdNovember 2020 in University Hospital Zurich.

The study is initiated by Prof. Dr. med Nils Kucher (also the Principal Investigator) in charge of the Clinic of Angiology at the University Hospital Zurich, Switzerland.

Prof. Dr. med Nils Kucher was excited to initiate the study and said, "Over the past decade, a few RCTs have compared the efficacy and safety of drug-coated (mainly paclitaxel-coated) devices vs. that of uncoated ones, and demonstrated a significant reduction in restenosis rates, late lumen loss, and incidence of target lesion re-vascularization. However, the size of these trials was often too small to draw firm conclusions concerning major clinical outcomes. Moreover, substantial heterogeneity of the study populations and too restrictive eligibility criteria limited their external validity, leading to a difficult interpretation of the results of meta-analyses. Indeed, these trials adopted surrogate (and rather subjective) outcomes as the primary outcome, such as vessel patency and target limb re-vascularization, which may be difficult to objectively judge in the setting of an open-label trial, rather than ´hard´ objective clinical endpoints, such as major amputation or urgent revascularization due to critical limb ischemia. The aim of the SirPAD trial is to compare the efficacy, as defined by a composite of clinically relevant non-subjective 'hard' outcomes (major amputation and target lesion re-vascularization for critical limb ischemia), of sirolimus-coated vs. uncoated balloon angioplasty for peripheral artery disease in patients."

www.conceptmedical.com[7]

Photo:https://mma.prnasia.com/media2/1329810/enrolment_of_the_first_patient_in_the_sirpad.jpg?p=medium600[8]

Logo: https://mma.prnasia.com/media2/1244676/Concept_Medical_Logo.jpg?p=medium600[9]

Source: Concept Medical Inc.

References

  1. ^ Concept Medical Inc., (www.conceptmedical.com)
  2. ^ SirPAD (www.conceptmedical.com)
  3. ^ SirPAD (www.conceptmedical.com)
  4. ^ MagicTouch PTA (www.conceptmedical.com)
  5. ^ MagicTouch PTA (www.conceptmedical.com)
  6. ^ MagicTouch PTA (www.conceptmedical.com)
  7. ^ www.conceptmedical.com (www.conceptmedical.com)
  8. ^ https://mma.prnasia.com/media2/1329810/enrolment_of_the_first_patient_in_the_sirpad.jpg?p=medium600 (mma.prnasia.com)
  9. ^ https://mma.prnasia.com/media2/1244676/Concept_Medical_Logo.jpg?p=medium600 (mma.prnasia.com)

Read more https://www.prnasia.com/story/archive/3184609_AE84609_0

Business Times

The Fears Australians Have About Getting Involved With Cryptocurr…

Cryptocurrency is no longer a fringe topic. It is discussed in boardrooms, on trading apps, and at suburban barbecues. Yet ...

The Evolution of Retail: From Bricks and Mortar to Online — What’…

Retail has always been a mirror of society. As populations grew, cities formed, technology advanced, and lifestyles chang...

The main-street comeback: how family-run food businesses are thri…

Walk down almost any Australian main street right now—whether it’s a coastal strip, an inner-suburban high street, or a c...

The Times Features

How to beat the post-holiday blues

As the summer holidays come to an end, many Aussies will be dreading their return to work and st...

One Nation surges above Coalition in Newspoll as Labor still well ahead, in contrast with other polls

The aftermath of the Bondi terror attacks has brought about a shift in polling for the Albanese ...

The Fears Australians Have About Getting Involved With Cryptocurrency

Cryptocurrency is no longer a fringe topic. It is discussed in boardrooms, on trading apps, and at...

The Quintessential Australian Road Trip

Mallacoota to Coolangatta — places to stay and things to see There are few journeys that captur...

Fitstop Just Got a New Look - And It’s All About Power, Progress and Feeling Strong

Fitstop has unveiled a bold new brand look designed to match how its members actually train: strong...

What We Know About Zenless Zone Zero 2.6 So Far

Zenless Zone Zero is currently enjoying its 2.5 version update with new characters like Ye Shunguang...

For Young People, Life Is an All-New Adventure. For Older People, Memories of Good Times and Lost Friends Come to Mind

Life does not stand still. It moves forward relentlessly, but it does not move the same way for ...

Single and Ready to Mingle – the Coffee Trend Australians Can Expect in 2026

Single-origin coffee is expected to increase in popularity among coffee drinkers over the next 12 ...

The Evolution of Retail: From Bricks and Mortar to Online — What’s Next?

Retail has always been a mirror of society. As populations grew, cities formed, technology advan...